<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00820352</url>
  </required_header>
  <id_info>
    <org_study_id>BO-001</org_study_id>
    <secondary_id>EUDRACT Number: 2008-005514-40</secondary_id>
    <nct_id>NCT00820352</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Bosentan in Patients With Diastolic Heart Failure and Secondary Pulmonary Hypertension</brief_title>
  <acronym>BADDHY</acronym>
  <official_title>Endothelin Receptor Blockade in Heart Failure With Diastolic Dysfunction and Pulmonary Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Teaching Hospital Hall in Tirol</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Teaching Hospital Hall in Tirol</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Heart failure is a major medical and socioeconomic problem in western industrial countries,
      especially with aging populations. Heart failure with normal left ventricle systolic function
      (heart failure with preserved ejection fraction, HFPEF, heart failure with normal ejection
      fraction, HFNEF) are common causes of hospitalization mainly in the elderly population and
      are frequently associated with pulmonary hypertension. It is commonly seen, that patients
      with left heart disease and pulmonary hypertension with right ventricle dysfunction have a
      worse prognosis.

      The investigators hypothesize, that an additional treatment with Bosentan in this patients
      will improve their exercise capacity, symptoms, hemodynamics and quality of life.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Heart Failure with preserved ejection fraction is with more than 50% of cases the most common
      form of heart failure. Typically patients are elderly women with arterial hypertension.
      Mortality, hospitalization rates due to heart failure and in-hospital complications do not
      differ significantly from patients with systolic heart failure. However there are some
      subgroups of HFPEF-patients with a worse prognosis, for example up to 30% of patients develop
      secondary pulmonary hypertension and thus right ventricle dysfunction. Increased
      right-ventricle systolic pressure is associated with increased mortality in patients with all
      forms of heart failure.

      There is a lack of evidence about HFPEF. Drugs for treating systolic heart failure showed no
      improvement in mortality and prognosis. Diuretics are just able to relieve symptoms. There
      are no clinical trials concerning HFPEF with secondary pulmonary hypertension.

      The endothelin system is not only activated in PAH, but also in pulmonary venous hypertension
      and congestive heart failure, where ET-1 levels rise with the severity of secondary pulmonary
      hypertension. Pulmonary congestion leads to endothelial dysfunction that results in increased
      levels of Endothelin-1 (ET-1).

      ET-1 is a potent vasoconstrictor. In pulmonary arterial vessels the ETA receptor is the
      predominant receptor (ratio of ETA to ET B = 9:1), which is responsible for vasoconstriction
      and remodeling of the pulmonal vasculature. In heart failure the ETA receptor is upregulated.
      Elevated plasma ET-1 levels correlate with pulmonary artery pressure (PAP), pulmonary
      vascular resistance (PVR) and inversely with peak exercise capacity.

      Recent clinical and laboratory findings indicate comparable pathophysiological mechanisms in
      pulmonary hypertension secondary to left ventricular dysfunction and pulmonary arterial
      hypertension. Yet, despite an expanding application in pulmonary artery hypertension,
      according to current opinion, the oral dual endothelin (ETA/ETB) antagonist bosentan is not
      indicated for PVH caused by left ventricle / left atrial pressure overload and preserved
      systolic function. However, there are several studies which show some effects of pulmonary
      vessel dilating drugs in PAH and left ventricle dysfunction.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in 6 minute waling distance after 12 weeks of bosentan (or placebo) treatment</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in 6 minute walking distance after 24 weeks (12 weeks bosentan or placebo treatment and 12 weeks follow-up)</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in hemodynamics assessed by echocardiography after 12 and 24 weeks</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to clinical worsening after 12 and 24 weeks</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>levels of NTpBNP, CRP and Endothelin-1 after 12 and 24 weeks</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life assessment (SF-36 and Minnesota Living With Heart Failure Score) after 12 and 24 weeks</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event count after 12 and 24 weeks</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Heart Failure, Diastolic</condition>
  <condition>Hypertension, Pulmonary</condition>
  <arm_group>
    <arm_group_label>bosentan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this arm receive bosentan twice a day for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>patients in this arm receive 12 placebo twice a day for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bosentan</intervention_name>
    <description>4 weeks of oral bosentan 62,5 mg b.i.d., followed by 8 weeks of 125 mg b.i.d.</description>
    <arm_group_label>bosentan</arm_group_label>
    <other_name>Ro 47.0203</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo twice a day for 12 weeks</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinically signs or history of congestive heart failure NYHA II-III (Fatigue, dyspnea
             on exertion, lung crepitations, pulmonary edema, ankle and or lower leg swelling,
             jugular pressure enhancement, hepatomegaly)

          -  Echocardiographic signs of diastolic dysfunction (heart failure with normal ejection
             fraction)

          -  Right ventricle enlargement with pulmonary hypertension

          -  6 minute walking distance &gt; 150 m &lt; 400 m

          -  Right Heart Catheterization: Mean PAP &gt; 25 mmHg, PCWP &gt; 15 mmHg

        Echocardiographic requirements for definition of heart failure with normal ejection
        fraction

          -  E/E` &gt; 15, or

          -  E/E` &gt; 8 + NTpBNP &gt; 220 pg/ml, or

          -  E/E` &gt; 8 + E:A &lt; 0.5 + DT &gt; 280 ms or

          -  Ard-Ad &gt; 30 ms or

          -  atrial enlargement or

          -  atrial fibrillation

          -  NTpBNP &gt; 220 pg/ml + combination

          -  IVRT - IVRTm &lt; 0 septal und lateral

        Echocardiographic requirements for pulmonary hypertension and right ventricle dysfunction

          -  RVEDD &gt; 30 mm short axis parasternal, and

          -  one of the following:

               -  Tricuspid valve regurgitation velocity (TRV) &gt; 3 m/s;

               -  RV-annular systolic velocity &lt; 10 cm/sec (TDI)

               -  TAPSE &lt; 18 mm

        Exclusion Criteria:

          -  Patients who are not on guideline conform treatments for cardiovascular disease.

          -  Left ventricle systolic dysfunction (EF &lt; 50 %), aortic stenosis with peak gradient
             (instantane) &gt; 40 mm Hg,moderate and severe aortic insufficiency

          -  moderate and severe mitral regurgitation,

          -  acute coronary disease, stable coronary artery disease or peripheral vascular disease
             limiting exercise.

          -  Other causes of pulmonary - artery - hypertension:

               -  relevant obstructive ventilatory disease &gt; grade II (lung functions tests)

               -  collagen disease (Tests: MSCT and ANA, ANCA),

               -  chronic thrombo- embolic pulmonary arterial hypertension (MSCT),

               -  sleep disorder.

               -  HIV, HCV, HBV infection.

               -  Drug related PAH.

          -  Orthopaedic disease, immobility, inability to perform 6MWT and cancer.

          -  Liver disease Child-Pugh B and C, three fold above normal elevated liver enzymes,

          -  anaemia Hb &lt; 10 mg/dl,

          -  other specific treatment of pulmonary arterial hypertension including other endothelin
             receptor blockers, phosphodiesterase inhibitors, prostaglandins and L-arginin

          -  drug therapy with glibenclamide, rifampicin, tacrolimus, sirolimus, cyclosporine A

          -  known adverse reactions to bosentan and

          -  pregnancy and lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wilhelm Grander, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Teaching Hospital Hall i.T.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Mostviertel Waidhofen/Ybbs</name>
      <address>
        <city>Waidhofen</city>
        <state>Lower Austria</state>
        <zip>3340</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Teaching Hospital Hall i.T.</name>
      <address>
        <city>Hall i. T.</city>
        <state>Tyrol</state>
        <zip>6060</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Teaching Hospital of the Elisabethinen, Linz</name>
      <address>
        <city>Linz</city>
        <state>Upper Austria</state>
        <zip>4010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Wels/Grieskirchen</name>
      <address>
        <city>Wels</city>
        <state>Upper Austria</state>
        <zip>4600</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Hohenems</name>
      <address>
        <city>Hohenems</city>
        <zip>6845</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Natters</name>
      <address>
        <city>Natters</city>
        <zip>6161</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Salzburg</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <reference>
    <citation>Kjaergaard J, Akkan D, Iversen KK, Kjoller E, Køber L, Torp-Pedersen C, Hassager C. Prognostic importance of pulmonary hypertension in patients with heart failure. Am J Cardiol. 2007 Apr 15;99(8):1146-50. Epub 2007 Mar 8.</citation>
    <PMID>17437745</PMID>
  </reference>
  <reference>
    <citation>Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006 Jul 20;355(3):251-9.</citation>
    <PMID>16855265</PMID>
  </reference>
  <reference>
    <citation>Shah SJ, Gheorghiade M. Heart failure with preserved ejection fraction: treat now by treating comorbidities. JAMA. 2008 Jul 23;300(4):431-3. doi: 10.1001/jama.300.4.431.</citation>
    <PMID>18647986</PMID>
  </reference>
  <reference>
    <citation>Sanderson JE. Heart failure with a normal ejection fraction. Heart. 2007 Feb;93(2):155-8. Epub 2005 Dec 30. Review.</citation>
    <PMID>16387829</PMID>
  </reference>
  <reference>
    <citation>Yip GW, Wang M, Wang T, Chan S, Fung JW, Yeung L, Yip T, Lau ST, Lau CP, Tang MO, Yu CM, Sanderson JE. The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction. Heart. 2008 May;94(5):573-80. doi: 10.1136/hrt.2007.117978. Epub 2008 Jan 20.</citation>
    <PMID>18208835</PMID>
  </reference>
  <reference>
    <citation>Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, Haouzi A, Gong Y, Liu PP. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med. 2006 Jul 20;355(3):260-9.</citation>
    <PMID>16855266</PMID>
  </reference>
  <reference>
    <citation>Bursi F, Weston SA, Redfield MM, Jacobsen SJ, Pakhomov S, Nkomo VT, Meverden RA, Roger VL. Systolic and diastolic heart failure in the community. JAMA. 2006 Nov 8;296(18):2209-16.</citation>
    <PMID>17090767</PMID>
  </reference>
  <reference>
    <citation>Tribouilloy C, Rusinaru D, Mahjoub H, Soulière V, Lévy F, Peltier M, Slama M, Massy Z. Prognosis of heart failure with preserved ejection fraction: a 5 year prospective population-based study. Eur Heart J. 2008 Feb;29(3):339-47. Epub 2007 Dec 22.</citation>
    <PMID>18156618</PMID>
  </reference>
  <reference>
    <citation>Sweitzer NK, Lopatin M, Yancy CW, Mills RM, Stevenson LW. Comparison of clinical features and outcomes of patients hospitalized with heart failure and normal ejection fraction (&gt; or =55%) versus those with mildly reduced (40% to 55%) and moderately to severely reduced (&lt;40%) fractions. Am J Cardiol. 2008 Apr 15;101(8):1151-6. doi: 10.1016/j.amjcard.2007.12.014. Epub 2008 Feb 20.</citation>
    <PMID>18394450</PMID>
  </reference>
  <reference>
    <citation>Onishi K, Ohno M, Little WC, Cheng CP. Endogenous endothelin-1 depresses left ventricular systolic and diastolic performance in congestive heart failure. J Pharmacol Exp Ther. 1999 Mar;288(3):1214-22.</citation>
    <PMID>10027861</PMID>
  </reference>
  <reference>
    <citation>Moraes DL, Colucci WS, Givertz MM. Secondary pulmonary hypertension in chronic heart failure: the role of the endothelium in pathophysiology and management. Circulation. 2000 Oct 3;102(14):1718-23.</citation>
    <PMID>11015353</PMID>
  </reference>
  <reference>
    <citation>Lewis GD, Shah R, Shahzad K, Camuso JM, Pappagianopoulos PP, Hung J, Tawakol A, Gerszten RE, Systrom DM, Bloch KD, Semigran MJ. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation. 2007 Oct 2;116(14):1555-62. Epub 2007 Sep 4.</citation>
    <PMID>17785618</PMID>
  </reference>
  <reference>
    <citation>Galié N, Manes A, Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc Res. 2004 Feb 1;61(2):227-37. Review.</citation>
    <PMID>14736539</PMID>
  </reference>
  <reference>
    <citation>Cowburn PJ, Cleland JG. Endothelin antagonists for chronic heart failure: do they have a role? Eur Heart J. 2001 Oct;22(19):1772-84. Review.</citation>
    <PMID>11549299</PMID>
  </reference>
  <reference>
    <citation>Cowburn PJ, Cleland JG, McDonagh TA, McArthur JD, Dargie HJ, Morton JJ. Comparison of selective ET(A) and ET(B) receptor antagonists in patients with chronic heart failure. Eur J Heart Fail. 2005 Jan;7(1):37-42.</citation>
    <PMID>15642529</PMID>
  </reference>
  <reference>
    <citation>Opitz CF, Ewert R, Kirch W, Pittrow D. Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter? Eur Heart J. 2008 Aug;29(16):1936-48. doi: 10.1093/eurheartj/ehn234. Epub 2008 Jun 17. Review.</citation>
    <PMID>18562303</PMID>
  </reference>
  <reference>
    <citation>Galiè N, Beghetti M, Gatzoulis MA, Granton J, Berger RM, Lauer A, Chiossi E, Landzberg M; Bosentan Randomized Trial of Endothelin Antagonist Therapy-5 (BREATHE-5) Investigators. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation. 2006 Jul 4;114(1):48-54. Epub 2006 Jun 26.</citation>
    <PMID>16801459</PMID>
  </reference>
  <reference>
    <citation>Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, Simonneau G. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002 Mar 21;346(12):896-903. Erratum in: N Engl J Med 2002 Apr 18;346(16):1258.</citation>
    <PMID>11907289</PMID>
  </reference>
  <reference>
    <citation>Sitbon O, Badesch DB, Channick RN, Frost A, Robbins IM, Simonneau G, Tapson VF, Rubin LJ. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest. 2003 Jul;124(1):247-54.</citation>
    <PMID>12853530</PMID>
  </reference>
  <reference>
    <citation>Zolk O, Quattek J, Sitzler G, Schrader T, Nickenig G, Schnabel P, Shimada K, Takahashi M, Böhm M. Expression of endothelin-1, endothelin-converting enzyme, and endothelin receptors in chronic heart failure. Circulation. 1999 Apr 27;99(16):2118-23.</citation>
    <PMID>10217651</PMID>
  </reference>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2009</study_first_submitted>
  <study_first_submitted_qc>January 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2009</study_first_posted>
  <last_update_submitted>June 27, 2014</last_update_submitted>
  <last_update_submitted_qc>June 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 30, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Teaching Hospital Hall in Tirol</investigator_affiliation>
    <investigator_full_name>Wilhelm Grander, M.D.</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <keyword>HFNEF</keyword>
  <keyword>HFPEF</keyword>
  <keyword>Secondary Pulmonary Hypertension</keyword>
  <keyword>Endothelin Receptor Blockade</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Heart Failure, Diastolic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bosentan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

